Drug Trial Radar · NCT06625957
Clinical Trial to Evaluate the Safety and Efficacy of NTCB02-1 in Patients Who Require Parenteral Nutrition
Last checked: Nov 19, 2026Latest source record: Jan 7, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
60
Planned (sponsor's estimate)
Start
Dec 4, 2024
Primary completion
Jul 18, 2025
Study completion Jul 18, 2025
Sponsor
- Lead sponsor
- Yuhan CorporationIndustry
- Sponsor type
- Industry
- First posted
- Oct 3, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 19 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A Randomized, Open-labeled, Multi-center, Active-controlled, Parallel-group Phase 3 Clinical Trial to Evaluate the Safety and Efficacy of NTCB02-1 versus NTCB-C in patients who require parenteral nutrition
Conditions
- Parenteral Nutrition
Interventions
NTCB02-1Drug
3 Days infusion
NTCB-CDrug
3 Days infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Occurance rate of adverse drug reactionTime frame: Day 1 to day 4
Locations
5 sites in 1 country. Site status is shown where the registry gives one.
National Cancer Center
Gyeonggi-do, Goyang-si, South Korea · Recruiting
Chonnam National University Hwasun Hospital
Jeollanam-do, Hwasun-gun, South Korea · Recruiting
Jeonbuk National University Hospital
Jeollabuk-do, Jeonju-si, South Korea · Recruiting
Severance Hospital
Seoul, Seodaemun-gu, South Korea · Recruiting
Seoul National University Bundang
Gyeonggi-do, Seongnam-si, South Korea · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.